AU5890899A - A method for measuring a patient's ability to metabolise certain drugs - Google Patents

A method for measuring a patient's ability to metabolise certain drugs

Info

Publication number
AU5890899A
AU5890899A AU58908/99A AU5890899A AU5890899A AU 5890899 A AU5890899 A AU 5890899A AU 58908/99 A AU58908/99 A AU 58908/99A AU 5890899 A AU5890899 A AU 5890899A AU 5890899 A AU5890899 A AU 5890899A
Authority
AU
Australia
Prior art keywords
patient
ability
measuring
certain drugs
metabolise
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU58908/99A
Inventor
Dan Hauzenberger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SANGTEC MOLECULAR DIAGNOSTICS AB
Original Assignee
Sangtec Medical AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sangtec Medical AB filed Critical Sangtec Medical AB
Publication of AU5890899A publication Critical patent/AU5890899A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C12N9/0077—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14) with a reduced iron-sulfur protein as one donor (1.14.15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6858—Allele-specific amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2531/00—Reactions of nucleic acids characterised by
    • C12Q2531/10—Reactions of nucleic acids characterised by the purpose being amplify/increase the copy number of target nucleic acid
    • C12Q2531/113—PCR
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2563/00—Nucleic acid detection characterized by the use of physical, structural and functional properties
    • C12Q2563/131—Nucleic acid detection characterized by the use of physical, structural and functional properties the label being a member of a cognate binding pair, i.e. extends to antibodies, haptens, avidin
AU58908/99A 1998-08-28 1999-08-25 A method for measuring a patient's ability to metabolise certain drugs Abandoned AU5890899A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9802897 1998-08-28
SE9802897 1998-08-28
PCT/SE1999/001449 WO2000012757A1 (en) 1998-08-28 1999-08-25 A method for measuring a patient's ability to metabolise certain drugs

Publications (1)

Publication Number Publication Date
AU5890899A true AU5890899A (en) 2000-03-21

Family

ID=20412399

Family Applications (1)

Application Number Title Priority Date Filing Date
AU58908/99A Abandoned AU5890899A (en) 1998-08-28 1999-08-25 A method for measuring a patient's ability to metabolise certain drugs

Country Status (4)

Country Link
EP (1) EP1108065A1 (en)
JP (1) JP2002523111A (en)
AU (1) AU5890899A (en)
WO (1) WO2000012757A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0021286D0 (en) * 2000-08-30 2000-10-18 Gemini Genomics Ab Identification of drug metabolic capacity
DE10237691B4 (en) * 2002-08-15 2010-01-28 Biotez Berlin-Buch Gmbh Biochemisch-Technologisches Zentrum Method for the detection of single nucleotide polymorphisms (SNP) in genes of drug metabolism and test kit for carrying out the method
EP1561823A1 (en) * 2004-02-04 2005-08-10 Biotez Berlin-Buch GmbH Method for the detection of single nucleotid polymorphisms (SNP) of genes of drug metabolism and test system for performing such a method
CA2571817A1 (en) * 2004-06-30 2006-01-12 Tm Bioscience Pgx, Inc. Method of detecting mutations in the gene encoding cytochrome p450-2c9
CA2575422A1 (en) * 2004-07-30 2006-02-02 Tm Bioscience Pgx, Inc. Method of detecting mutations in the gene encoding cytochrome p450-2c19
GR1005451B (en) * 2005-09-20 2007-02-21 Medicon Hellas A.E. Method for detecting single nucleotide variations in a nucleotide sequnce using dry/lyophilized reagents.
US20090269756A1 (en) * 2006-11-30 2009-10-29 Arkray, Inc. Primer set for amplifying cyp2c19 gene, reagent for amplifying cyp2c19 gene containing the same, and the uses thereof
EP2111465B1 (en) * 2007-01-22 2013-12-04 Siemens Healthcare Diagnostics Inc. Reagents and methods for detecting cyp2c9 polymorphisms

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL97222A (en) * 1990-02-16 1995-08-31 Orion Yhtymae Oy Method and reagent for determining specific nucleotide variations
US5912120A (en) * 1992-04-09 1999-06-15 The United States Of America As Represented By The Department Of Health And Human Services, Cloning, expression and diagnosis of human cytochrome P450 2C19: the principal determinant of s-mephenytoin metabolism
AU2860295A (en) * 1994-06-16 1996-01-05 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Defects in drug metabolism
JPH1014585A (en) * 1996-07-05 1998-01-20 S R L:Kk New oligonucleotide primer and examination of point mutation in exon 4 of human cytochrome p450 2c19 gene using the same

Also Published As

Publication number Publication date
JP2002523111A (en) 2002-07-30
WO2000012757A1 (en) 2000-03-09
EP1108065A1 (en) 2001-06-20

Similar Documents

Publication Publication Date Title
EP0755690A3 (en) Hypodermic cannula
PL322579A1 (en) 2-methyl-thiene-benzodiazeoin prparation for oral administration
AU7606798A (en) Computer system for evaluating a client's condition
AU4164896A (en) Apparatus for delivering fluid to a patient
AU3967795A (en) Method of sterilizing a pharmaceutical composition
AU7390596A (en) Exciter-detector unit for measuring physiological parameters
AUPN411195A0 (en) Medicinal composition
AU8126198A (en) A skin care and protection composition and a method for preparation thereof
AU7430696A (en) Syringe for epidural catheter
AU6046998A (en) Method of measuring physiological function
PL314732A1 (en) S(+)-ethodolac preparations for oral administration
IL119417A0 (en) Drug for Parkinson's disease
AUPP713498A0 (en) A method of detecting blood
AU6431496A (en) A new skin preparation composition
AU6243099A (en) Method and device for administering gas to a patient
AU5890899A (en) A method for measuring a patient's ability to metabolise certain drugs
AU6066896A (en) Substituted cinnamic acid guanidides, a process for their preparation, their use as medicaments or diagnostic agents and medicaments comprising them
AU1108001A (en) A method of taking measurements in a patient's fully edentulous jaws
AU6998196A (en) Medicinal composition for diabetes
AU5570899A (en) Purified human papillomavirus
FR2732217B1 (en) SOLID ADMINISTRATION FORM FOR ORAL USE
AU2002232419A1 (en) Clinician's assistant system
AU2150600A (en) System and method for providing a dental diagnosis
AU6335098A (en) Non-invasive radiographic method for analyzation of a body element
AU5347996A (en) Preparation for oral administration

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase
TH Corrigenda

Free format text: IN VOL 14, NO 23, PAGE(S) 4188-4191 UNDER THE HEADING APPLICATIONS LAPSED, REFUSED OR WITHDRAWN PLEASE DELETE ALL REFERENCE TO APPLICATION NO. 53857/99 AND 58908/99

MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase